PRIALT is not an opiate and cannot prevent or relieve the symptoms associated with the withdrawal of opiates. To avoid withdrawal syndrome when opiate withdrawal is necessary, do not abruptly reduce or withdraw opioid medications.
What is PRIALT used for?
PRIALT is a prescription medicine used to treat severe chronic pain in adults who cannot take other treatments or when other treatments do not work, stop working, or cause bothersome side effects.
Where is PRIALT found?
The active substance in Prialt, ziconotide, is a copy of a natural substance called omega-conopeptide, which is found in the venom of a type of sea snail. Ziconotide acts by blocking special pores called calcium channels on the surface of the nerve cells that transmit the pain signals.
How is PRIALT administered?
PRIALT should be administered intrathecally (IT) by or under the direction of a physician experienced in the technique of IT administration and who is familiar with the drug and device labeling. PRIALT is not intended for intravenous administration.
Is Prialt FDA approved?
On Dec. 28, the FDA approved ziconotide intrathecal (IT) infusion (Prialt, made by Elan Corporation, plc), for the management of severe chronic pain in patients for whom IT therapy is warranted, and who are intolerant or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.
Does Medicare cover Prialt?
Medicare patients are responsible for 20% coinsurance which may be covered by secondary or supplemental insurance. They can help you with insurance and reimbursement guidance for PRIALT.
What is Prialt made of?
Ziconotide (SNX–111; Prialt), also called intrathecal ziconotide (ITZ) because of its administration route, is an atypical analgesic agent for the amelioration of severe and chronic pain. Derived from Conus magus, a cone snail, it is the synthetic form of an ω-conotoxin peptide.
When was ziconotide approved by FDA?
Approval Date: 12/28/2004.
